Regeneron Pharmaceuticals Reports Promising Phase 3 Trial Results for Libtayo in High-Risk Cutaneous Squamous Cell Carcinoma
31/5 14:11
Libtayo shows significant efficacy in reducing recurrence risk in high-risk CSCC patients after surgery, pending regulatory approval....